Capital Fund Management S.A. Arcus Biosciences, Inc. Transaction History

Capital Fund Management S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$14.59 - $18.48 $747,489 - $946,785	51,233 Added 377.38%	64,809 $987,000
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $201,332 - $273,963	13,576 New	13,576 $256,000
Q2 2022 Aug 12, 2022	BUY	$17.23 - $37.73 $1.66 Million - $3.63 Million	96,224 New	96,224 $2.44 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.